论文部分内容阅读
目前,在改善心力衰竭患者的预后方面,主要通过减少患者的功能性二尖瓣反流(FMR)。2017年7月25日,《欧洲心脏病杂志》发表了一项最新相关研究,在最佳药物治疗(OMT)和其他因素引起心脏射血分数降低(HFr EF)的情况下,评估FMR对心力衰竭患者预后的影响。研究纳入576例HFr EF患者长期观察。基线水平上检测心功能(NYHA分级),超声心动图,侵入性血流动力学和生化指标(NT-proBNP,MR-proANP,MR-proADM,CT-proET-1,copeptin)。中位随访62个月,其中47%
At present, it is mainly through reducing the patient’s functional mitral regurgitation (FMR) in improving the prognosis of patients with heart failure. On July 25, 2017, the European Journal of Cardiology published a new study that assessed the effects of FMR on cardiac performance with reduced cardiac ejection fraction (HFr EF) due to optimal medical treatment (OMT) and other factors The prognosis of patients with failure. Long-term observation of 576 patients with HFr EF was included in the study. Cardiac function (NYHA class), echocardiography, invasive hemodynamics and biochemical markers (NT-proBNP, MR-proANP, MR-proADM, CT-proET-1, copeptin) were measured at baseline. The median follow-up of 62 months, of which 47%